![]() |
Name |
5, 7-Dihydroxy-3-hydroxymethyl-2-methylchromone
|
Molecular Formula | C11H10O5 | |
IUPAC Name* |
5,7-dihydroxy-3-(hydroxymethyl)-2-methylchromen-4-one
|
|
SMILES |
Cc1oc2cc(O)cc(O)c2c(=O)c1CO
|
|
InChI |
InChI=1S/C11H10O5/c1-5-7(4-12)11(15)10-8(14)2-6(13)3-9(10)16-5/h2-3,12-14H,4H2,1H3
|
|
InChIKey |
JTVXUEYEPGRLSS-UHFFFAOYSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 222.2 | ALogp: | 1.0 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 90.9 | Aromatic Rings: | 2 |
Heavy Atoms: | 16 | QED Weighted: | 0.679 |
Caco-2 Permeability: | -4.876 | MDCK Permeability: | 0.00000850 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.806 |
Human Intestinal Absorption (HIA): | 0.014 | 20% Bioavailability (F20%): | 0.049 |
30% Bioavailability (F30%): | 0.793 |
Blood-Brain-Barrier Penetration (BBB): | 0.022 | Plasma Protein Binding (PPB): | 79.84% |
Volume Distribution (VD): | 0.813 | Fu: | 35.34% |
CYP1A2-inhibitor: | 0.908 | CYP1A2-substrate: | 0.877 |
CYP2C19-inhibitor: | 0.056 | CYP2C19-substrate: | 0.063 |
CYP2C9-inhibitor: | 0.071 | CYP2C9-substrate: | 0.835 |
CYP2D6-inhibitor: | 0.203 | CYP2D6-substrate: | 0.4 |
CYP3A4-inhibitor: | 0.076 | CYP3A4-substrate: | 0.162 |
Clearance (CL): | 6.681 | Half-life (T1/2): | 0.948 |
hERG Blockers: | 0.008 | Human Hepatotoxicity (H-HT): | 0.081 |
Drug-inuced Liver Injury (DILI): | 0.681 | AMES Toxicity: | 0.492 |
Rat Oral Acute Toxicity: | 0.048 | Maximum Recommended Daily Dose: | 0.111 |
Skin Sensitization: | 0.586 | Carcinogencity: | 0.026 |
Eye Corrosion: | 0.054 | Eye Irritation: | 0.951 |
Respiratory Toxicity: | 0.138 |